Skip to main content

The Role of Epigenetic Modifications in Cancer Progression

183kviews
Editorial08 January 2021
Editorial: The Role of Epigenetic Modifications in Cancer Progression

Epigenetics describes multimodal molecular mechanisms that confer a certain phenotype on cell without a change in genotype (1). Chromatin remodelers (e.g. SWI/SNF complex) control opening and shutting a gateway for transcription factors to access genomic loci, and chemical modifications on chromatins (e.g. DNA methylation and histone modifications) regulate transcriptional activities, both resulting in a large-scale alteration of transcriptional landscape (2,3). Small noncoding RNAs also modulate a transcriptome by targeting a large number of sequence-matched mRNAs and sustain an epigenetic state by triggering and maintaining epigenetic gene silencing of chromatin modifier (4).In the post-genomic era, epigenetic regulations have been widely investigated to understand the molecular mechanisms underlying transcriptional addiction and phenotypic diversity in cancer cells. In this research topic, we have organized a collection of reviews and original research articles that shed light on the epigenetic regulations of cancer cell identity and fate. Chemical modifications in histone proteins, such as acetylation, methylation, phosphorylation, and ubiquitination, alter the structure of chromatin and renew the transcriptional landscape. Since the manner of histone modifications is often dysregulated in cancer, understanding the molecular mechanism by which the modifications contribute to cancer progression is important. Illiano et al.

2,834 views

6 citations

Abstract Despite the recent advances in chemotherapeutic treatments against cancer, some types of highly aggressive and invasive cancer develop drug resistance against conventional therapies, which continues to be a major problem in the fight against cancer. In recent years, studies of alterations of DNA methylome have given us a better understanding of the role of DNA methylation in the development of tumors. DNA methylation is an epigenetic change that promotes the covalent transfer of methyl groups to DNA. DNA methylation suppresses gene expression through the modulation of the transcription machinery access to the chromatin or through the recruitment of methyl binding proteins. DNA methylation is regulated mainly by DNA methyltransferases. Aberrant DNA methylation contributes to tumor progression, metastasis, and resistance to current anti-tumoral therapy. Aberrant DNA methylation may occur through hypermethylation in the promoter regions of tumor suppressor genes, which leads to their silencing, while hypomethylation in the promoter regions of oncogenes can activate them. In this review, we discuss the impact of dysregulated methylation in certain genes, which impact signaling pathways associated with apoptosis avoidance, metastasis, and resistance to therapy. The analysis of methylome has revealed patterns of global methylation, which regulate important signaling pathways involved in therapy resistance in different cancer types, such as breast, colon, and lung cancer, among other solid tumors. This analysis has provided gene-expression signatures of methylated region-specific DNA that can be used to predict the treatment outcome in response to anti-cancer therapy. Additionally, changes in cancer methylome have been associated with the acquisition of drug resistance. We also review treatments with demethylating agents that, in combination with standard therapies, seem to be encouraging, as tumors that are in early stages can be successfully treated. On the other hand, tumors that are in advanced stages can be treated with these combination schemes, which could sensitize tumor cells that are resistant to the therapy. We propose that rational strategies, which combine specific demethylating agents with conventional treatment, may improve overall survival in cancer patients.

18,862 views

173 citations

ORIGINAL RESEARCH
16 September 2020
KDM5c Promotes Colon Cancer Cell Proliferation Through the FBXW7-c-Jun Regulatory Axis
Haishan Lin, 3 more and Bangwei Cao

5,009 views

32 citations

ORIGINAL RESEARCH
3 July 2020
The Role of Transcriptional Factor Brachyury on Cell Cycle Regulation in Non-small Cell Lung Cancer
Jingyi Xu, 6 more and Jun Shen

3,658 views

7 citations

Transcription factor brachyury, with a DNA-binding T-domain, regulates posterior mesoderm formation and notochord development through binding with highly conserved palindromic consensus sequence in a variety of organisms. The absence of brachyury expression in majority of adult normal tissues and exclusive tumor-specific expression provides the potential to be developed into a novel and promising diagnostic and therapeutic target in cancer. As a sensitive and specific marker in the diagnosis of chordoma, brachyury protein has been verified to involve in the process of carcinogenesis and progression of chordoma and several epithelial carcinomas in various studies, but the mechanism by which brachyury promotes tumor cells migrate, invade and metastasis still remains less clear. To this end, we attempt to summarize the literature on the upstream regulatory pathway of brachyury transcription and downstream controlling network by brachyury activation, all of which involve in both the embryonic development and tumor progression. We present the respective correlation of brachyury expression with tumor progression, distant metastasis, survival rate and prognosis in several types of tumor samples (including chordoma, lung cancer, breast carcinoma, and prostate cancer), and various brachyury gain-of-function and loss-of-function experiments are summarized to explore its specific role in respective tumor cell line in vitro. In addition, we also discuss another two programs relating to brachyury function: epithelial-to-mesenchymal transition (EMT) and cell cycle control, both of which implicate in the regulation of brachyury on biological behavior of tumor cells. This review will provide an overview of the function of master transcriptional factor brachyury, compare the similarities and differences of its role between embryonic development and carcinogenesis, and list the evidence on which brachyury-target therapies have the potential to help control advanced cancer populations.

14,458 views

65 citations

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
The development of resistance to anti-cancer therapeutics remains one of the core issues preventing the improvement of survival rates in cancer. Therapy resistance can arise in a multitude of ways, including the accumulation of epigenetic alterations in cancer cells. By remodeling DNA methylation patterns or modifying histone proteins during oncogenesis, cancer cells reorient their epigenomic landscapes in order to aggressively resist anti-cancer therapy. To combat these chemoresistant effects, epigenetic modifiers such as DNA hypomethylating agents, histone deacetylase inhibitors, histone demethylase inhibitors, along with others have been used. While these modifiers have achieved moderate success when used either alone or in combination with one another, the most positive outcomes were achieved when they were used in conjunction with conventional anti-cancer therapies. Epigenome modifying drugs have succeeded in sensitizing cancer cells to anti-cancer therapy via a variety of mechanisms: disrupting pro-survival/anti-apoptotic signaling, restoring cell cycle control and preventing DNA damage repair, suppressing immune system evasion, regulating altered metabolism, disengaging pro-survival microenvironmental interactions and increasing protein expression for targeted therapies. In this review, we explore different mechanisms by which epigenetic modifiers induce sensitivity to anti-cancer therapies and encourage the further identification of the specific genes involved with sensitization to facilitate development of clinical trials.

12,912 views

59 citations

ORIGINAL RESEARCH
12 June 2020
Antagonizing CDK8 Sensitizes Colorectal Cancer to Radiation Through Potentiating the Transcription of e2f1 Target Gene apaf1
Bin Chen, 8 more and Guoping Zhao

4,932 views

20 citations

ORIGINAL RESEARCH
14 May 2020
ALKBH4 Functions as a Suppressor of Colorectal Cancer Metastasis via Competitively Binding to WDR5
Chaoqin Shen, 15 more and Baoqin Xuan

4,993 views

23 citations

ORIGINAL RESEARCH
16 April 2020
ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma
Qianping Chen, 11 more and Chunlin Shao

8,736 views

58 citations

ORIGINAL RESEARCH
20 December 2019
Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2
Yangfan Xu, 9 more and Xianqun Fan

8,295 views

54 citations

ORIGINAL RESEARCH
15 October 2019
Silencing of ARL14 Gene Induces Lung Adenocarcinoma Cells to a Dormant State
Fei Guo, 7 more and Chunlin Shao

4,319 views

26 citations